CSL Behring launches new dosing app
pharmafile | June 27, 2012 | News story | Medical Communications | Beriplex P/N, CSL Behring, app, digital
Biotherapy firm CSL Behring UK has launched an app for doctors to aid the management of its anaesthetic treatment Beriplex P/N.
The ‘Dosing Calculator App’ was launched at The General Anaesthetists in Training Annual Scientific Meeting in Glasgow.
Available on both iPhone and Android handsets, it will calculate the correct dose and volume of Beriplex P/N to be infused based upon entry of only two key pieces of information: the patient’s weight and their initial international normalised ratio (INR).
Users then simply tap ‘calculate’ to obtain the dose required. CSL Behring says this is important for healthcare professionals in cases where quicker information is needed to make effective, timely decisions such as in an emergency setting.
New research indicates a high level of smartphone usage amongst healthcare professionals in the UK, with around 80% owning a device according to a recent survey. Behring is hoping to capitalise on this high use by launching its app to increase awareness of its drug among its key audience.
Eddie Owens, general manager of CSL Behring UK, said: “We see that healthcare professionals are clearly using mobile technology to access health information and for us to engage with this growing target audience, we need to be present in this medium.
“The new Beriplex P/N Dosing Calculator App aims to meet the demand that healthcare professionals have to access sound medical data from anywhere and at anytime.”
Ben Adams is the reporter for Pharmafocus and InPharm.com and author of the DigiBlog site. He can be contacted via: email or Twitter.
Related Content
CSL Behring’s angioedema treatments receives NICE recommendation
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending …
CSL Behring’s therapy for hereditary angioedema receives positive assessment in Germany
CSL Behring has announced a key milestone for its hereditary angioedema (HAE) therapy, garadacimab, following …
First UK patient treated with CSL Behring’s gene therapy for Haemophilia B
CSL Behring has announced that the first patient in the UK has received HEMGENIX (etranacogene …
